Presidio Management

Management

H. Daniel Perez, MD, President & Chief Executive Officer: Over 25 years of professional experience; Venture Partner, Bay City Capital; President & Chief Executive Officer, Berlex; Professor of Medicine, UCSF.

Richard Colonno, PhD, Chief Scientific Officer: Over 25 years experience in virology and drug discovery and development; VP, Infectious Disease Drug Discovery, Bristol-Myers Squibb; Senior Director, Antiviral Research, Merck Sharp & Dohme Research Labs; Research Scientist, DuPont; Research Fellow, Roche Institute of Molecular Biology.

Leo Redmond, MBA, Chief Financial Officer: Over 20 years of financial experience, including supporting R&D, commercial, administrative, and business development groups; Senior Director of Finance, Genentech, Inc.; CFO and Secretary, Genentech Foundation for Biomedical Sciences.

Nathaniel Brown, MD, Chief Medical Officer: Over 20 years of clinical drug development experience, with leadership roles in six product registrations in the U.S. and globally; Executive Vice President of Clinical Development and Chief Medical Officer, Idenix Pharmaceuticals; Director of Clinical and Scientific Affairs for Infectious Disease and Hepatitis, Glaxo Wellcome, Inc.

Leping Li, PhD, Vice President of Chemistry: Over 20 years experience in drug discovery as a medicinal chemist; Sr. Director of Chemistry, Presidio Pharmaceuticals; Scientific Director of Chemistry, Tularik/Amgen; Research Investigator, Abbott Laboratories.

Tom Anderton, JD, Vice President of IP and Legal Affairs: Over 15 years experience in developing and implementing intellectual property portfolios and legal strategy; Associate General Counsel, Monogram Biosciences; Lead Attorney, Genencor International; Head of Intellectual Property, SUGEN; Associate, Evenson McKeown.

Eric Ruby, MS, Vice President of Regulatory Affairs: Over 20 years experience in regulatory affairs and compliance in both the private and public sector; Senior Director, Regulatory Affairs, Alnylam Pharmaceuticals; Senior Director, Regulatory Affairs, Vertex Pharmaceuticals; Director, Regulatory Affairs, Control Delivery Systems; Manager, Regulatory Affairs, Mallinckrodt Veterinary; Branch Chief, Division of Chemistry, Food and Drug Administration (FDA).

	Management \| Board of Directors
	Management H. Daniel Perez, MD, President & Chief Executive Officer: Over 25 years of professional experience; Venture Partner, Bay City Capital; President & Chief Executive Officer, Berlex; Professor of Medicine, UCSF. Richard Colonno, PhD, Chief Scientific Officer: Over 25 years experience in virology and drug discovery and development; VP, Infectious Disease Drug Discovery, Bristol-Myers Squibb; Senior Director, Antiviral Research, Merck Sharp & Dohme Research Labs; Research Scientist, DuPont; Research Fellow, Roche Institute of Molecular Biology. Leo Redmond, MBA, Chief Financial Officer: Over 20 years of financial experience, including supporting R&D, commercial, administrative, and business development groups; Senior Director of Finance, Genentech, Inc.; CFO and Secretary, Genentech Foundation for Biomedical Sciences. Nathaniel Brown, MD, Chief Medical Officer: Over 20 years of clinical drug development experience, with leadership roles in six product registrations in the U.S. and globally; Executive Vice President of Clinical Development and Chief Medical Officer, Idenix Pharmaceuticals; Director of Clinical and Scientific Affairs for Infectious Disease and Hepatitis, Glaxo Wellcome, Inc. Leping Li, PhD, Vice President of Chemistry: Over 20 years experience in drug discovery as a medicinal chemist; Sr. Director of Chemistry, Presidio Pharmaceuticals; Scientific Director of Chemistry, Tularik/Amgen; Research Investigator, Abbott Laboratories. Tom Anderton, JD, Vice President of IP and Legal Affairs: Over 15 years experience in developing and implementing intellectual property portfolios and legal strategy; Associate General Counsel, Monogram Biosciences; Lead Attorney, Genencor International; Head of Intellectual Property, SUGEN; Associate, Evenson McKeown. Eric Ruby, MS, Vice President of Regulatory Affairs: Over 20 years experience in regulatory affairs and compliance in both the private and public sector; Senior Director, Regulatory Affairs, Alnylam Pharmaceuticals; Senior Director, Regulatory Affairs, Vertex Pharmaceuticals; Director, Regulatory Affairs, Control Delivery Systems; Manager, Regulatory Affairs, Mallinckrodt Veterinary; Branch Chief, Division of Chemistry, Food and Drug Administration (FDA). Presidio Pharmaceuticals, Inc.